governance and ethics
A private UK company infirst Ltd is not listed on any public stock exchange. The business is managed by a Leadership Team with many decades of industry experience. This team strive to manage the business through the development and application of consistent and cohesive policies, guidelines, processes and decision making authorities. The Leadership team is accountable to the Board of Directors.
Manfred is Non-Executive Director and Chairman of infirst Limited’s parent company, Flarin Holding Ltd. Manfred was previously CEO of the Infirst Healthcare Group and spent 25 highly successful years with GlaxoSmithKline Consumer Health including commercial responsibilities for Europe and North America. Manfred has given long service to industry associations having been on the Boards of CHPA in the USA, AESGP in Europe and PAGB in the UK. Manfred holds further non-executive Board roles in the USA, Germany and Scandinavia.
Andrew has over 30 years of experience in managerial roles in Pharmaceuticals and Consumer Healthcare including over 10 years as a Vice President Consumer Healthcare for Latin America, and Central and Eastern Europe in GSK. He worked with infirst Healthcare Limited as a consultant responsible for Business Development and Flarin before taking up his current position in November 2019. He is a graduate of Durham and Hull Universities.
Philip joined Infirst Healthcare as Chief Financial Officer in November 2018 and was appointed Chief Financial Officer for infirst Limited in October 2019. He is a chartered accountant and has been CFO of a variety of public and privately owned companies since 1990. Philip is an engineering graduate of Oxford University and started his career at Deloitte Haskins & Sells in London and in the oil and energy industries in financial management, commercial and consultancy roles.
Gregory is Non-Executive Director of infirst Healthcare Ltd and Chief Executive Officer of SEEK (formerly known as PepTcell) which he founded in 2004, after a distinguished 20 year career in investment banking at Deutsche Bank and UBS. He has worked on numerous mergers, acquisitions and structured finance deals in the healthcare industry, including mergers by GlaxoSmithKline, Aventis and Pfizer. Gregory has also worked in project finance for major pharmaceutical company clients such as Roche, Merck and Novartis. He has a wealth of experience in advising and working with medical research companies across Australasia, USA and Europe.
Gregory is a qualified Chartered Accountant and has spent many years researching scientific medical issues, specifically related to the immune system. He has had several scientific papers published, many specialising in the area of research into peptides and is listed as an inventor in numerous patents for cancer, HIV, mosquito-borne diseases and influenza.
wait until something is "seriously wrong" before seeing their GP